title: Targeted therapy and hand-foot skin reaction in advanced renal cell carcinoma.
abstract: BACKGROUND
  Targeted therapy has significantly prolonged the survival of patients with advanced renal cell carcinoma (RCC). As first-line treatment, sunitinib, temsirolimus and bevacizumab plus IFN-alpha are demonstrated to prolong progression-free survival and/or overall survival. As second-line treatment, sorafenib was active mainly for patients in whom cytokine therapy failed. Recently, second-line treatment with everolimus has been shown to benefit patients progressing through tyrosine kinase inhibitors. Meanwhile, FDA has just approved pazopanib for the treatment of patients with advanced RCC. Various toxicities were associated with these agents. These toxicities were generally well tolerated. However, a high frequency of severe skin and bone marrow toxicities has been reported in Asian countries.
  
  
  METHODS
  We have reviewed the literature of current targeted therapeutic agents and hand-foot skin reaction (HFSR) in advanced RCC available in MEDLINE and meeting reports of ASCO, ECCO-ESMO and the 2009 Genitourinary Cancers Symposium.
  
  
  RESULTS
  Readers will know of the efficacy and safety, including HFSR, of current targeted therapy.
  
  
  CONCLUSIONS
  Careful monitoring and appropriate management of the toxicities, especially HFSR, are needed.
authors.affiliation: Chang Gung University College of Medicine, Chang Gung Memorial Hospital, Department of Dermatology, Taoyuan, Taiwan.
authors.forename: Chih-Hsun
authors.initials: CH
authors.lastname: Yang
authors.forename: Cheng-Keng
authors.initials: CK
authors.lastname: Chuang
authors.forename: Jia-Juan
authors.initials: JJ
authors.lastname: Hsieh
authors.forename: John Wen-Cheng
authors.initials: JW
authors.lastname: Chang
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology; D016503:Drug Delivery Systems / Q000379:methods*; D005528:Foot / Q000473:pathology; D006225:Hand / Q000473:pathology; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D012871:Skin Diseases / Q000139:chemically induced* / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents